TipRanks
Advertisement
Advertisement
Indaptus Therapeutics Reports Q2 Results Amid Strategic Pivot
PremiumCompany AnnouncementsIndaptus Therapeutics Reports Q2 Results Amid Strategic Pivot
2M ago
Indaptus Therapeutics files to sell 18.86M shares of common stock for holders
Premium
The Fly
Indaptus Therapeutics files to sell 18.86M shares of common stock for holders
3M ago
Indaptus Therapeutics Announces Private Placement of Common Stock
Premium
Company Announcements
Indaptus Therapeutics Announces Private Placement of Common Stock
3M ago
Indaptus Shareholders Approve Major Charter and Capital Changes
PremiumCompany AnnouncementsIndaptus Shareholders Approve Major Charter and Capital Changes
7M ago
Indaptus Therapeutics Reprices Warrants to Bolster Shareholder Support
Premium
Company Announcements
Indaptus Therapeutics Reprices Warrants to Bolster Shareholder Support
8M ago
Indaptus Therapeutics cuts executive pay, director stays on
Premium
Company Announcements
Indaptus Therapeutics cuts executive pay, director stays on
9M ago
Indaptus Therapeutics reports Q3 EPS ($2.98) vs ($9.04) last year
PremiumThe FlyIndaptus Therapeutics reports Q3 EPS ($2.98) vs ($9.04) last year
11M ago
Indaptus Therapeutics Advances Cancer Treatment with DECOY20 Clinical Study
Premium
Company Announcements
Indaptus Therapeutics Advances Cancer Treatment with DECOY20 Clinical Study
11M ago
Indaptus Therapeutics Reports Mixed Results in Clinical Trial
Premium
Company Announcements
Indaptus Therapeutics Reports Mixed Results in Clinical Trial
1y ago

Trending

Name
Price
Price Change
S&P 500
―
Dow Jones
―
Nasdaq 100
―